In CLL, the most frequent mechanisms of resistance observed in ibrutinib treated patients are point mutations: the BTK mutation C481S (a mutation in BTK altering the configuration of the cysteine binding site) and mutations in phospholipase C gamma 2 (PCLg2) [50]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.